Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 695500 open-label extension in rheumatoid arthritis
NL-OMON40517Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by Boehringer Ingelheim. Started Aug 2014; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON40517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40517.